Sirolimus Rx cycle length: how long is a dosing cycle?

Last updated 2026-07-27

What does "cycle length" mean for rapamycin?

In bodybuilding or steroid contexts, a "cycle" means a defined stretch of dosing followed by a defined break. Rapamycin doesn't really work that way in the off-label longevity world. Almost every protocol people discuss is a dosing interval, not a cycle: a fixed dose taken once a week, or once every two weeks, indefinitely, with no planned discontinuation. That distinction matters because the question "what's the cycle length" often gets asked by people expecting a 6-week-on, 2-week-off structure. That's not what's happening here. The intermittent part of "intermittent dosing" refers to the gap between doses within a week or two, not a multi-month on/off block. The rationale for weekly dosing rather than daily dosing comes from pharmacokinetics, not longevity trial data. Sirolimus (the generic name; brand name Rapamune when approved for transplant patients) has an average terminal elimination half-life around 57 to 63 hours in stable renal transplant patients, according to the FDA-approved prescribing information for Rapamune ^[1]. That's roughly two and a half days. A once-daily dose, which is standard in transplant medicine, keeps blood levels essentially continuous. Once-weekly dosing, which is the pattern almost all off-label longevity users follow, lets levels rise and then fall close to zero before the next dose, mimicking the pulsed exposure pattern used in some of the mouse lifespan studies.

How often do people actually take it off-label?

The dominant pattern in off-label use is once weekly. A smaller group uses twice weekly or once every 10 to 14 days. Daily dosing, the FDA-approved transplant schedule, is rarely used by people pursuing longevity purposes because it produces much more sustained immune suppression. The weekly interval isn't arbitrary. It traces back to a study from Mannick and colleagues testing an mTOR inhibitor (RAD001, an everolimus derivative closely related to rapamycin) on influenza vaccine response in adults over 65, using intermittent dosing schedules including 5mg once weekly and 20mg once weekly ^[2]. That paper found the intermittent regimens improved vaccine antibody response without the infection-rate penalty seen with continuous daily dosing, and it's the single most cited piece of human data behind the pulsed-dosing idea. It was not a lifespan study. It ran six weeks. It measured vaccine response, not aging. For exact numbers, see Sirolimus Rx dosage and the Sirolimus Rx dosage calculator, which walk through weight-based and fixed-dose approaches people use with their prescriber.

Is there an official on/off cycle backed by human trials?

No. There is no FDA-approved or clinically validated cycle length for longevity use, because rapamycin has no FDA approval for longevity use at all. Sirolimus is approved to prevent organ rejection after kidney transplant, and related formulations (Fyarro, Hyftor) are approved for specific rare conditions, perivascular epithelioid cell tumor and tuberous sclerosis complex skin lesions respectively ^[3][4]. None of those approvals involve intermittent weekly dosing for aging. Every weekly or biweekly schedule circulating in longevity communities is an extrapolation: partly from the Mannick vaccine study ^[2], partly from mouse dosing schedules in the NIA Interventions Testing Program, and partly from clinician experience managing transplant patients' side effects. None of it has been tested in a human lifespan or healthspan trial. That's the central honest fact of this whole topic, and it's worth restating plainly: nobody has run a completed trial showing any human dosing schedule, cyclic or continuous, extends human lifespan.

What does the mouse data actually say about dosing schedule?

The strongest data anchor for rapamycin and lifespan is the National Institute on Aging's Interventions Testing Program (ITP), which has tested rapamycin in genetically heterogeneous mice across three cohorts starting in 2006. The ITP found that rapamycin fed continuously starting at 9 months of age extended median lifespan by about 10 percent in males and 18 percent in females in the original 2009 cohort, published in Nature ^[5]. Later cohorts starting rapamycin earlier, or at higher doses, produced larger effects, with some encapsulated higher-dose regimens extending median female lifespan over 20 percent ^[6]. Critically, the ITP mice were fed rapamycin continuously in their chow, not cycled on and off. That's a real mismatch with how most off-label human users actually dose. The pulsed weekly-in-humans approach borrows its logic from short-term immune and metabolic studies, not from the lifespan-extension studies themselves. If you want the mouse data to be your evidence base, continuous low-dose exposure is actually what's been tested, not a weekly pulse. That gap between what's proven in mice and what's practiced in humans is something every serious reader should sit with before treating any specific interval as settled science.

Why do people cycle on and off (or avoid doing so)?

The main reason to avoid continuous daily dosing is immunosuppression. Sirolimus works by inhibiting mTOR, a protein complex that regulates cell growth and immune cell proliferation. Continuous daily dosing, the way it's used in transplant patients, produces sustained immunosuppression, which is exactly the point in that population but a real liability in someone who isn't trying to prevent organ rejection. The FDA-approved label for Rapamune carries a boxed warning about increased susceptibility to infection and the possible development of lymphoma with sirolimus use ^[1]. Weekly or biweekly dosing is the off-label compromise: hit peak mTOR inhibition, let blood levels fall close to baseline before the next dose, and in theory let immune function recover between doses. Whether that theory holds in practice for healthy, non-transplant adults over months or years hasn't been tested in a controlled human trial. Short-term data, like the six-week Mannick study ^[2], is the best available signal, and even that showed increased rates of minor infections in some dosing arms alongside the improved vaccine response. Some people also cite metabolic effects as a reason to pulse dosing rather than run continuous. Sirolimus can raise fasting glucose, triglycerides, and LDL cholesterol; the FDA-approved label documents hyperlipidemia and new-onset diabetes as adverse effects in transplant populations taking it daily ^[1]. Weekly-dose users report these effects less often, but there's no dedicated long-term human study quantifying that difference in a longevity-use population.

What's a typical weekly protocol length before reassessing?

Most clinicians running off-label rapamycin protocols reassess at 3 to 6 months, not because there's a data-backed cutoff, but because that's a reasonable interval to recheck labs (lipid panel, fasting glucose, CBC, kidney function) and see how someone is tolerating a weekly dose. That's a monitoring cadence, not a pharmacological cycle. A typical pattern looks like: start low, often 1 to 2 mg once weekly for oral dosing (doses vary by formulation, weight, and prescriber judgment; see the dosage calculator for how these are commonly derived), hold that dose for 8 to 12 weeks, get labs rechecked, and adjust up or down based on tolerability and lab trends. Some users continue for years at a stable weekly dose with periodic lab checks rather than following any defined stop-start schedule. There is no evidence that stopping for a period and restarting produces a better or worse outcome than continuous weekly dosing. It's not a proven strategy either way. Anyone telling you a specific number of weeks-on, weeks-off is optimal is speaking from personal practice or forum consensus, not from a completed trial.

How does half-life shape the weekly interval?

The roughly 60-hour half-life is why weekly (not daily, not monthly) became the default off-label interval. After about 5 half-lives, a drug is considered essentially cleared from the body, which for sirolimus works out to roughly 12 to 13 days ^[1]. A once-weekly dose means the next dose lands well before full clearance, but with several days of lower exposure between the peak and the next dose, which is the pulsed pattern people are aiming for. A once-every-two-weeks schedule, sometimes used by people wanting less frequent immune suppression, lets blood levels approach near-total clearance between doses. A twice-weekly schedule keeps levels more continuously elevated, closer to the daily transplant pattern. None of these variants has its own dedicated aging-outcome trial in humans; the choice among them is a judgment call made with a prescriber based on tolerability, labs, and side effect profile, not a settled protocol. For the full pharmacokinetic picture, including how compounded and reconstituted formulations behave, see Sirolimus Rx half life and how to reconstitute Sirolimus Rx.

What side effects show up within a cycle, and when?

Mouth ulcers (technically aphthous stomatitis) are the most commonly reported early side effect with weekly rapamycin dosing, often appearing 24 to 72 hours after a dose and resolving within a few days. This mirrors the stomatitis reported in sirolimus's FDA-approved label, where mouth ulcers were among the most frequent adverse reactions in the original transplant trials ^[1]. People on weekly protocols often notice ulcers cluster right after the dose, then fade before the next one, which is one practical marker some point to as evidence the pulsed pattern lets tissues recover between doses. That's an observation, not a validated mechanism. Other effects to watch across a dosing interval include mild swelling in the ankles or lower legs (peripheral edema), elevated triglycerides or LDL on follow-up labs, and, less commonly, joint pain or headache in the day or two after dosing. Infection risk is the effect people worry about most, given sirolimus's boxed warning for increased susceptibility to infection ^[1], though the intermittent human data on infection rates specifically in healthy off-label users doesn't exist; the infection-rate data we have comes from continuous-dosing transplant populations and the six-week Mannick vaccine study ^[2].

Should the cycle length change based on age, sex, or health status?

There's no validated answer here, and that's worth saying directly rather than guessing. The ITP mouse data does show a sex difference in magnitude of lifespan extension (females showing larger median lifespan gains than males in several cohorts) ^[5][6], which has led some clinicians to informally discuss whether dosing might differ by sex, but that's extrapolation from rodent data, not a human dosing guideline. Age, kidney function, and concurrent medications are the factors that actually change real-world dosing decisions, because they affect sirolimus clearance and interact with known risks. The FDA-approved label notes significant drug interactions with strong CYP3A4 inhibitors (like ketoconazole) and inducers (like rifampin), and flags that dose adjustments are needed in hepatic impairment ^[1]. Anyone with kidney disease, liver disease, uncontrolled diabetes, or a history of cancer needs that discussed explicitly with a prescriber before any protocol, weekly or otherwise, is started.

What does a provider-reviewed protocol actually look like?

A provider-reviewed protocol means a licensed prescriber evaluates your labs and health history, decides whether off-label sirolimus is appropriate at all, sets a starting dose and interval, and schedules follow-up labs, rather than a person self-directing based on forum posts. This is the structure Sirolimus Rx is built around: connecting people who want to pursue this off-label route with providers who review candidacy and monitor labs over time, and identifying the pharmacy partner that fulfills the prescription once it's written. That structure doesn't change the underlying evidence gap. No provider, however careful, can hand you a human trial proving a specific cycle length extends lifespan, because that trial doesn't exist yet. What a provider-reviewed process can do is catch contraindications, order the right baseline and follow-up labs (lipid panel, fasting glucose or HbA1c, CBC, renal function), and adjust the interval if side effects like persistent mouth ulcers or lab abnormalities show up. That's risk management, not proof of benefit.

What should you ask before starting any interval?

Ask what baseline labs will be checked before the first dose, how soon follow-up labs happen (commonly 4 to 8 weeks in), and what specific findings would trigger a dose reduction or discontinuation. Ask directly whether the prescriber has experience with off-label rapamycin dosing specifically, since this is a different pattern from the daily transplant regimen most nephrologists and transplant physicians are trained on. Ask about drug interactions relevant to your other medications, given sirolimus's documented CYP3A4 interactions ^[1]. And ask, honestly, whether the person or service you're working with is clear that this is off-label use without a completed human lifespan trial behind it. That last point should not be a hard question to get a straight answer to. If it is, that's a signal to look elsewhere. For practical mechanics once a protocol is set, see Sirolimus Rx how to inject and Sirolimus Rx injection sites (relevant for injectable formulations some protocols use) alongside the oral dosing details in Sirolimus Rx dosage.

Frequently asked questions

What is the standard rapamycin cycle length for anti-aging use?

There isn't one. Most off-label protocols use continuous once-weekly or biweekly dosing rather than a defined on/off cycle. The interval comes from sirolimus's roughly 60-hour half-life and short-term human immune studies, not a completed human lifespan trial. Treat any claimed "standard cycle" as an informal convention, not an approved protocol.

How long is one dosing interval for weekly rapamycin?

Seven days is the interval, meaning one dose is taken, then none for six days, then the next dose. This is repeated indefinitely rather than stopped after a set number of cycles. The seven-day spacing is meant to let blood levels fall between doses given the drug's roughly 57 to 63 hour elimination half-life documented in the FDA-approved prescribing information for Rapamune.

Do you need to take breaks from rapamycin every few months?

There's no data showing scheduled multi-month breaks improve outcomes versus continuous weekly dosing. Some prescribers pause dosing temporarily for a specific reason, like an active infection, elective surgery, or a lab abnormality, but that's a clinical pause, not a planned cycle. Nobody has published a trial comparing continuous weekly dosing against a break-and-restart schedule for longevity purposes.

Is rapamycin the same as sirolimus?

Yes. Sirolimus is the generic drug name; rapamycin is the original scientific name for the same molecule, first isolated from soil bacteria on Easter Island (Rapa Nui). Rapamune is the FDA-approved brand name version. All refer to the same compound used in transplant medicine and studied off-label for longevity.

What's the evidence that intermittent dosing works better than daily dosing?

The main human data point is a study by Mannick and colleagues testing intermittent low-dose mTOR inhibition on vaccine response in adults over 65, which found improved antibody response with less infection risk than continuous daily dosing over six weeks. It did not measure lifespan or aging outcomes, so it supports a safety and immune-function rationale, not a proven longevity benefit.

Has any human trial shown rapamycin extends lifespan?

No completed human trial has shown rapamycin or sirolimus extends human lifespan. The strong lifespan data comes entirely from mouse studies, particularly the NIA Interventions Testing Program, which found median lifespan extensions of roughly 10 to 25 percent depending on cohort, dose, and sex. Human data is limited to short-term studies on immune function, vaccine response, and skin aging markers.

How long until you'd see benefits from a rapamycin cycle?

There's no validated timeline for longevity benefit in humans, since no human aging-outcome trial exists. Short-term human studies have measured effects like improved vaccine antibody response within 6 weeks and skin changes over several months in small trials, but nothing establishing when, or whether, longevity benefits appear in people.

Can you switch between weekly and biweekly dosing mid-protocol?

People do this in practice, usually to manage side effects like persistent mouth ulcers or lipid changes, but switching intervals should go through the prescriber who's tracking labs. There's no trial comparing outcomes between weekly and biweekly schedules, so any switch is a tolerability adjustment, not a move backed by comparative efficacy data.

What labs should be checked during a rapamycin protocol?

Common labs include a fasting lipid panel (sirolimus can raise triglycerides and LDL), fasting glucose or HbA1c, complete blood count, and kidney function tests. The FDA-approved label for Rapamune documents hyperlipidemia and new-onset diabetes as recognized adverse effects, which is why these are typically rechecked every 8 to 12 weeks in off-label monitoring.

Why do mouth ulcers happen with rapamycin, and do they mean you should stop?

Mouth ulcers (aphthous stomatitis) are among the most frequently reported adverse reactions in sirolimus's FDA-approved prescribing information. They often appear a day or two after dosing and resolve before the next dose in weekly protocols. Persistent or worsening ulcers should be reported to the prescriber, since dose reduction or interval changes may help, but this is a case-by-case clinical decision.

Is rapamycin FDA-approved for longevity or anti-aging use?

No. Sirolimus is FDA-approved to prevent kidney transplant rejection, and related formulations (Fyarro, Hyftor) are approved for specific rare tumor and skin conditions. Any use for aging, lifespan extension, or general longevity is entirely off-label and not supported by a completed human trial.

Does the mouse lifespan data actually use weekly dosing?

No. The NIA Interventions Testing Program studies fed rapamycin continuously through mouse chow, not on a weekly pulse. The once-weekly human dosing pattern is borrowed from separate short-term human immune studies, not from the mouse lifespan protocols themselves, which is a real gap between the strongest animal evidence and current human practice.

What's the difference between a rapamycin "cycle" and a dosing interval?

A cycle implies a defined period of use followed by a defined stop. A dosing interval is just the spacing between doses within an ongoing protocol, like once weekly, with no planned end date. Almost all off-label rapamycin protocols use a dosing interval structure, not a cycle-with-breaks structure.

Sources

1. FDA, Rapamune (sirolimus) prescribing information (label revision, 2015), NDA 021083: Elimination half-life, boxed warning on infection/lymphoma risk, hyperlipidemia and new-onset diabetes adverse effects, CYP3A4 interactions
2. Mannick et al., Science Translational Medicine (2018): Intermittent low-dose mTOR inhibition improved influenza vaccine response in adults over 65 over a short trial period
3. FDA, Fyarro (sirolimus protein-bound particles) approval announcement: Fyarro is FDA-approved for advanced malignant perivascular epithelioid cell tumor (PEComa), not for longevity
4. FDA, Hyftor (sirolimus topical gel) prescribing information, NDA 213478: Hyftor is FDA-approved for facial angiofibroma associated with tuberous sclerosis complex
5. Harrison et al., Nature (2009), NIA Interventions Testing Program: Rapamycin fed continuously starting at 9 months extended median lifespan roughly 10% in males and 18% in females
6. Miller et al., Aging Cell (2014), NIA Interventions Testing Program: Higher-dose encapsulated rapamycin extended median lifespan further, over 20% in some female cohorts